原发性胆汁性胆管炎合并骨质疏松症的诊断及处理

张文; 陈姝延; 吕婷婷; 尤红

doi:10.3969/j.issn.1001-5256.2021.10.004

原发性胆汁性胆管炎合并骨质疏松症的诊断及处理

DOI: 10.3969/j.issn.1001-5256.2021.10.004

首都医科大学附属北京友谊医院肝病中心，国家消化系统疾病临床医学研究中心，北京 100050

详细信息

通信作者:
尤红，youhong30@sina.com

中图分类号: R575.22
计量
- 文章访问数: 584
- HTML全文浏览量: 206
- PDF下载量: 126
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-10
- 录用日期: 2021-08-24
- 出版日期: 2021-10-20

Diagnosis and management of primary biliary cholangitis with osteoporosis

National Clinical Research Center for Digestive Diseases, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

摘要

摘要: 原发性胆汁性胆管炎(PBC)是一种慢性进行性胆汁淤积性肝病，多发于中老年女性，最终可导致肝硬化和肝衰竭。骨质疏松症是PBC患者的常见并发症，表现为骨量减少，骨折易感性增加。骨质疏松及其所致骨折严重影响PBC患者的生活质量，而随着PBC治疗策略的进步和人们预期寿命的增加，对PBC患者合并骨质疏松症的早期诊断及防治则显得尤为重要。现对PBC患者合并骨质疏松症的流行病学、发病机制及诊疗现状进行简要总结，同时提出目前面临的挑战及未来的研究方向。
- 肝硬化, 胆汁性 /
- 骨质疏松 /
- 诊断 /
- 治疗学
Abstract: Primary biliary cholangitis (PBC) is a chronic progressive cholestatic liver disease often observed in the middle-aged and elderly women and it can eventually lead to liver cirrhosis or liver failure. Osteoporosis is one of the common complications in PBC patients and is characterized by decreased bone mass and increased susceptibility to fractures. Osteoporosis and fractures caused by osteoporosis seriously affect the quality of life of PBC patients, and with the improvement of PBC treatment strategies and the increase in life expectancy, early diagnosis, prevention, and treatment of PBC with osteoporosis is of particular importance. This article briefly summarizes the epidemiology, pathogenesis, and diagnosis and treatment of patients with PBC and osteoporosis and proposes current challenges and future research directions.
- Liver Cirrhosis, Biliary /
- Osteoporosis /
- Diagnosis /
- Therapeutics

HTML全文

参考文献(39)

[1]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis)(2015)[J]. J Clin Hepatol, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004.
[2]	RUIZ-GASPÀ S, GUAÑABENS N, JURADO S, et al. Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases[J]. Gene, 2020, 725: 144167. DOI: 10.1016/j.gene.2019.144167.
[3]	Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis (2017)[J]. Chin J Osteoporosis, 2019, 25(3): 281-309. DOI: 10.3969/j.issn.1006-7108.2019.03.001. 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中国骨质疏松杂志, 2019, 25(3): 281-309. DOI: 10.3969/j.issn.1006-7108.2019.03.001.
[4]	DANFORD CJ, TRIVEDI HD, PAPAMICHAEL K, et al. Osteoporosis in primary biliary cholangitis[J]. World J Gastroenterol, 2018, 24(31): 3513-3520. DOI: 10.3748/wjg.v24.i31.3513.
[5]	GLASS LM, SU GL. Metabolic bone disease in primary biliary cirrhosis[J]. Gastroenterol Clin North Am, 2016, 45(2): 333-343. DOI: 10.1016/j.gtc.2016.02.009.
[6]	LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2019, 69(1): 394-419. DOI: 10.1002/hep.30145.
[7]	ZENG N, DUAN W, CHEN S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: A systematic review and meta-analysis[J]. Hepatol Int, 2019, 13(6): 788-799. DOI: 10.1007/s12072-019-09984-x.
[8]	TRIVEDI HD, DANFORD CJ, GOYES D, et al. Osteoporosis in primary biliary cholangitis: Prevalence, impact and management challenges[J]. Clin Exp Gastroenterol, 2020, 13: 17-24. DOI: 10.2147/CEG.S204638.
[9]	MARTIN P, DIMARTINI A, FENG S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Hepatology, 2014, 59(3): 1144-1165. DOI: 10.1002/hep.26972.
[10]	DANFORD CJ, TRIVEDI HD, BONDER A. Bone health in patients with liver diseases[J]. J Clin Densitom, 2020, 23(2): 212-222. DOI: 10.1016/j.jocd.2019.01.004.
[11]	RUIZ-GASPÀ S, GUAÑABENS N, ENJUANES A, et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts[J]. Eur J Clin Invest, 2010, 40(1): 25-34. DOI: 10.1111/j.1365-2362.2009.02230.x.
[12]	KAWELKE N, BENTMANN A, HACKL N, et al. Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation[J]. J Bone Miner Res, 2008, 23(8): 1278-1286. DOI: 10.1359/jbmr.080313.
[13]	RUIZ-GASPÀ S, GUAÑABENS N, JURADO S, et al. Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestatic-induced osteoporosis[J]. Liver Int, 2020, 40(11): 2767-2775. DOI: 10.1111/liv.14630.
[14]	CAO X. RANKL-RANK signaling regulates osteoblast differentiation and bone formation[J]. Bone Res, 2018, 6: 35. DOI: 10.1038/s41413-018-0040-9.
[15]	LIU W, ZHANG X. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review)[J]. Mol Med Rep, 2015, 11(5): 3212-3218. DOI: 10.3892/mmr.2015.3152.
[16]	SZALAY F, HEGEDUS D, LAKATOS PL, et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis[J]. J Hepatol, 2003, 38(4): 395-400. DOI: 10.1016/s0168-8278(02)00435-x.
[17]	FENG J, LIU S, MA S, et al. Protective effects of resveratrol on postmenopausal osteoporosis: Regulation of SIRT1-NF-κB signaling pathway[J]. Acta Biochim Biophys Sin (Shanghai), 2014, 46(12): 1024-1033. DOI: 10.1093/abbs/gmu103.
[18]	INVERNIZZI P, RANSOM M, RAYCHAUDHURI S, et al. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis[J]. Genes Immun, 2012, 13(6): 461-468. DOI: 10.1038/gene.2012.17.
[19]	ESTRADA K, STYRKARSDOTTIR U, EVANGELOU E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture[J]. Nat Genet, 2012, 44(5): 491-501. DOI: 10.1038/ng.2249.
[20]	TANG R, WEI Y, LI Z, et al. A common variant in CLDN14 is associated with primary biliary cirrhosis and bone mineral density[J]. Sci Rep, 2016, 6: 19877. DOI: 10.1038/srep19877.
[21]	GUAÑABENS N, CERDÁ D, MONEGAL A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis[J]. Gastroenterology, 2010, 138(7): 2348-2356. DOI: 10.1053/j.gastro.2010.02.016.
[22]	KEMMLER W, ENGELKE K, VON STENGEL S. Long-term exercise and bone mineral density changes in postmenopausal women—are there periods of reduced effectiveness?[J]. J Bone Miner Res, 2016, 31(1): 215-222. DOI: 10.1002/jbmr.2608.
[23]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
[24]	WANG Z, PENG C, WANG P, et al. Serum vitamin D level is related to disease progression in primary biliary cholangitis[J]. Scand J Gastroenterol, 2020, 55(11): 1333-1340. DOI: 10.1080/00365521.2020.1829030.
[25]	EASTELL R, ROSEN CJ, BLACK DM, et al. Pharmacological management of osteoporosis in postmenopausal women: An endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2019, 104 (5): 1595-1622. DOI: 10.1210/jc.2019-00221.
[26]	SANTOS LA, ROMEIRO FG. Diagnosis and management of cirrhosis-related osteoporosis[J]. Biomed Res Int, 2016, 2016: 1423462. DOI: 10.1155/2016/1423462.
[27]	BENETTI A, CROSIGNANI A, VARENNA M, et al. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: A controlled longitudinal study[J]. J Clin Gastroenterol, 2008, 42(3): 306-311. DOI: 10.1097/01.mcg.0000248017.31386.39.
[28]	KIM YH, JANG WG, OH SH, et al. Fenofibrate induces PPARα and BMP2 expression to stimulate osteoblast differentiation[J]. Biochem Biophys Res Commun, 2019, 520(2): 459-465. DOI: 10.1016/j.bbrc.2019.10.048.
[29]	ZHONG X, XIU LL, WEI GH, et al. Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation[J]. Acta Pharmacol Sin, 2011, 32(5): 591-600. DOI: 10.1038/aps.2011.15.
[30]	ZHONG X, XIU L, WEI G, et al. Bezafibrate prevents palmitate-induced apoptosis in osteoblastic MC3T3-E1 cells through the NF-κB signaling pathway[J]. Int J Mol Med, 2011, 28(4): 535-542. DOI: 10.3892/ijmm.2011.722.
[31]	NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375(7): 631-643. DOI: 10.1056/NEJMoa1509840.
[32]	RUDIC JS, GILJACA V, KRSTIC MN, et al. Bisphosphonates for osteoporosis in primary biliary cirrhosis[J]. Cochrane Database Syst Rev, 2011, (12): CD009144. DOI: 10.1002/14651858.CD009144.pub2.
[33]	GUAÑABENS N, MONEGAL A, CERDÁ D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis[J]. Hepatology, 2013, 58(6): 2070-2078. DOI: 10.1002/hep.26466.
[34]	TREEPRASERTSUK S, SILVEIRA MG, PETZ JL, et al. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis[J]. Am J Ther, 2011, 18(5): 375-381. DOI: 10.1097/MJT.0b013e3181d7e1d3.
[35]	ORMARSDÓTTIR S, MALLMIN H, NAESSÉN T, et al. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis[J]. J Intern Med, 2004, 256(1): 63-69. DOI: 10.1111/j.1365-2796.2004.01342.x.
[36]	LEVY C, HARNOIS DM, ANGULO P, et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: Results of a pilot study[J]. Liver Int, 2005, 25(1): 117-121. DOI: 10.1111/j.1478-3231.2005.01026.x.
[37]	SUGIMOTO T. Anti-RANKL monoclonal antibody Denosumab (AMG162)[J]. Clin Calcium, 2011, 21(1): 46-51.
[38]	ARASE Y, TSURUYA K, HIROSE S, et al. Efficacy and safety of 3-year denosumab therapy for osteoporosis in patients with autoimmune liver diseases[J]. Hepatology, 2020, 71(2): 757-759. DOI: 10.1002/hep.30904.
[39]	DANFORD CJ, EZAZ G, TRIVEDI HD, et al. The pharmacologic management of osteoporosis in primary biliary cholangitis: A systematic review and meta-analysis[J]. J Clin Densitom, 2020, 23(2): 223-236. DOI: 10.1016/j.jocd.2019.05.003.